Cancer Family
Trophoblastic Tumor
CI-CAN-00000376Explore in graph →
Non-malignant12 active trials1 approved drugs
Loading cancer entity…
Cancer Family
CI-CAN-00000376Explore in graph →
Clinical trials
82 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH |
| 2 |
| Jun 17, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials